Posts Tagged: "information disclosure statement"

Preparing an Information Disclosure Statement (IDS) can be stressful. The United States Patent and Trademark Office (USPTO) has very strict guidelines which must be followed precisely to avoid errors. Failure to adhere to these guidelines will result in additional costs and time spent in filing the Information Disclosure Statement (IDS). Often, errors are made due to changes in requirements made by the USPTO, failing to adhere to deadlines, and lack of providing adequate reference materials. While these mistakes can happen frequently, there are steps patent filers and intellectual property (IP) professionals can take to avoid errors. Below are some of the most common IDS-related mistakes made by patent filers and practitioners.

The USPTO recently announced the implementation of the first phase of the Access to Relevant Prior Art (RPA) Initiative. The initiative is being designed to reduce the burden placed upon patent applicants to comply with their duty of disclosure through the use of automated tools which import relevant prior art and other pertinent information into pending U.S. patent applications as quickly as possible.

The USPTO declined to initiate an inter partes review of two patents owned by Acorda Therapeutics, Inc. Acorda patents were challenged by the Coalition for Affordable Drugs, LLC, the entity formed by billionaire hedge fund manager Kyle Bass. I have to wonder whether this decision represents a shift in the worldview of the PTAB or whether they sought out a reason to deny the petition because it was filed by Kyle Bass. Unfortunately, I suspect these two denials have everything to do with who was behind the challenge and little to do with the merits of the challenge.